Ketamine & Esketamine: Conference Sessions

Cristina Cusin

Translating the ketamine and esketamine evidence base into safe clinical use for depression.

Depression

David Mischoulon · Cristina Cusin · Oliver Freudenreich · Abigail Donovan

Faculty discussion of psychosis and ketamine topics.

Antipsychotic Prescribing

Adrian Preda

Advanced pharmacologic and interventional options for depression unresponsive to first-line treatment.

Neuromodulation (ECT, TMS)Treatment-Resistant Depression

Gagan Joshi

Explores glutamate-modulating treatments for autism and associated psychiatric conditions.

Autism & Neurodevelopmental DisordersDrug Pipeline & Clinical Trials

Paul E. Croarkin

A clinical consultation breakfast reviewing evidence, safety, regulatory and ethical issues for TMS, ECT, electrical stimulation, ketamine/esketamine and emerging psychedelic approaches in youth with treatment-resistant disorders. Uses case-based discussion on patient selection and consent/assent.

Child & AdolescentNeuromodulation (ECT, TMS)Treatment-Resistant Depression

Jacob Lister · Michael H. Bloch · Ruin Moaddel · Carlos Zarate · Jennifer Dwyer

Investigates whether ketamine metabolites predict treatment response in adolescents with depression in a midazolam-controlled randomized trial.

Child & AdolescentDepressionPharmacogenomics & Precision Psychiatry

Courtney Miller · Paula Bolton · Jonathan Foley

Two published ketamine clinic studies: memory effects of treatment and IV versus intranasal efficacy comparison.

Treatment-Resistant Depression

Andrew J. Cutler · Kristian Dambrino

When and how to deploy glutamatergic agents in major depressive disorder to improve functional recovery.

Depression

Roger S. McIntyre

The glutamate hypothesis of depression and its therapeutic implications, from ketamine to emerging agents.

DepressionNeuroscience & Mechanisms

Tomas Palenicek · Luisa Pinto · Sophie Holmes · Annette Johansen

Psilocybin and ketamine effects on neurogenesis, synaptic plasticity, and the role of setting, from bench to PET imaging.

Neuroscience & MechanismsPsychedelics

Brittany Albright · Michael Asbach

Examines glutamatergic dysfunction in MDD and the evidence for current and emerging glutamate-targeting therapies in treatment-resistant depression.

Neuroscience & MechanismsTreatment-Resistant Depression

Michael Thase

Step-by-step algorithms for treatment-resistant bipolar depression — when to switch, augment, or combine — with evidence on newer agents such as lumateperone, cariprazine, and ketamine.

Antipsychotic PrescribingBipolar Disorder